Chapter 18 — Quiz

TB-500, Thymosin Alpha-1, and Other Recovery and Immune Peptides

Twenty-two items. Multiple choice, true/false with justification, and short answer. Answer key at the bottom, with reasoning rather than bare letters.

1. Thymosin β4 is a peptide of how many amino acids?

  • A. 15
  • B. 28
  • C. 43
  • D. 51

2. The compound marketed as "TB-500" is best described as:

  • A. Thymosin β4 sold under a different name
  • B. A short synthetic fragment marketed as corresponding to thymosin β4's actin-binding region
  • C. A recombinant version of thymosin β4 produced in cell culture
  • D. A structural analog of thymosin alpha-1

3. Thymosin alpha-1 is:

  • A. A fragment of thymosin β4
  • B. A 28-amino-acid peptide derived from prothymosin alpha
  • C. A synthetic analog of α-MSH
  • D. A cathelicidin

4. True or false, with one sentence of justification: Because thymosin β4 and thymosin alpha-1 share a family name, findings about one provide preliminary support for claims about the other.

5. Thymosin β4's best-established biochemical activity is:

  • A. Binding G-actin and buffering actin polymerization
  • B. Disrupting bacterial membranes
  • C. Regulating intestinal tight junctions
  • D. Antagonizing the growth hormone receptor

6. The animal repair literature for thymosin β4 is concentrated in which three areas?

  • A. Bone, cartilage, and ligament
  • B. Dermal wound healing, cardiac repair after injury, and corneal healing
  • C. Liver regeneration, kidney injury, and neuropathy
  • D. Muscle hypertrophy, tendon repair, and fracture healing

7. Which statement about the human evidence for TB-500 for tissue repair is accurate as of this writing?

  • A. Several randomized controlled trials have been completed with mixed results
  • B. One large randomized trial was completed and was negative
  • C. No completed randomized controlled human trials appear in the published literature
  • D. Human evidence exists but only in veterinary journals

8. Chapter 5 §5.3's fifth reason animal results fail to transfer — the one most readers forget — concerns:

  • A. Species differences in receptor structure
  • B. Publication filtering, because animal research is largely unregistered
  • C. Cost of animal facilities
  • D. The difficulty of blinding animal studies

9. Short answer. Explain in two or three sentences why this book declines to state how many animal studies exist for a given compound.

10. Thymosin alpha-1's regulatory status is:

  • A. Approved in the United States but not in Europe
  • B. Approved in a number of countries for defined indications; not FDA-approved in the United States
  • C. Withdrawn from all markets following safety findings
  • D. Approved nowhere; available only through research channels

11. According to §18.3, a compound approved by some major regulators and declined by others is most characteristically a sign that:

  • A. One regulator has made an error that will eventually be corrected
  • B. The compound is fraudulent
  • C. The evidence sits in a genuinely contestable middle, clearing some reasonable thresholds and not others
  • D. Political pressure was applied in the approving jurisdictions

12. True or false, with justification: An approval in another country for chronic hepatitis B supports using a compound for general immune support in a healthy adult.

13. LL-37 is:

  • A. A synthetic tripeptide fragment of α-MSH
  • B. A human cathelicidin antimicrobial peptide with additional immunomodulatory properties
  • C. An octapeptide studied for celiac disease
  • D. The actin-binding region of thymosin β4

14. §18.4 declines to issue a rating for LL-37 because:

  • A. The evidence is too weak to rate
  • B. LL-37 is not a peptide
  • C. Chapter 25 presents the evidence, and a rating issued without its evidence base is not something a reader can check
  • D. The compound is not commercially available

15. Larazotide is unusual among peptides because it is:

  • A. Absorbed orally with unusually high bioavailability
  • B. Taken orally and deliberately designed not to be absorbed, because its target is in the gut lumen
  • C. Delivered across the blood-brain barrier
  • D. Active only after enzymatic cleavage in the bloodstream

16. KPV is:

  • A. A 43-residue peptide
  • B. A tripeptide corresponding to the C-terminal fragment of α-MSH
  • C. A cathelicidin
  • D. A GLP-1 analog

17. Short answer. Name the four specifications missing from the claim "this peptide modulates and balances the immune system."

18. The fifth requirement of a real immune claim — beyond arm, assay, direction, and population — is:

  • A. A named manufacturer
  • B. Connection to a clinical outcome, because a shifted laboratory value is a surrogate
  • C. A stated duration of use
  • D. Independent laboratory verification of purity

19. True or false, with justification: The ❌ assigned to "immune modulation" as a claim form and the ❌ assigned to TB-500 for tissue repair mean the same thing.

20. The symmetric risk described in §18.7 arises because the mechanisms promoted for tissue repair — angiogenesis, proliferation, and cell survival — are:

  • A. Known to be carcinogenic in humans
  • B. The same processes a tumor requires
  • C. Impossible to measure
  • D. Unique to injured tissue

21. Which statement about cancer risk is consistent with §18.7?

  • A. Repair peptides have been shown to promote tumor growth in humans
  • B. Repair peptides have been shown not to promote tumor growth in humans
  • C. No causal link to human cancer is established for these compounds, and the question is also unstudied
  • D. The concern was investigated and resolved in the animal literature

22. Short answer. The Dossier distinguishes three states that "no evidence" wrongly merges. Name them, and say which one TB-500 primarily occupies and why that state is the most misleading.

Answer key **1. C — 43.** Thymosin β4 is a 43-amino-acid peptide. (A is BPC-157's length, B is thymosin alpha-1's, D is insulin's.) **2. B.** TB-500 is a laboratory code for a compound marketed as a short synthetic fragment, commonly described as corresponding to the actin-binding region. It is *not* thymosin β4, which makes A the single most common error about this compound and the one §18.1 exists to correct. **3. B.** Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha. It is not a fragment of thymosin β4 and is not structurally related to it in any useful sense. **4. False.** The shared word "thymosin" reflects a historical accident of isolation — both were originally identified in thymus-derived preparations — not a family resemblance that predicts anything. They differ in length, origin, activity, and evidence base. Treating them as siblings because of the name is the §18.1 error one taxonomic level up. **5. A.** Tβ4 binds G-actin, the free unpolymerized form, buffering the pool available for polymerization. This is textbook cell biology and is why the molecule appears in discussions of cell motility and wound closure. **6. B.** Dermal wound healing, cardiac repair after injury, and corneal healing. Corneal work has gone furthest toward human investigation, in part because the cornea's transparency makes healing unusually easy to observe. **7. C.** No completed randomized controlled human trials of the marketed compound for these endpoints appear in the published literature. Note that this is an accurate description of a search result, not a claim that the compound does nothing. **8. B — publication filtering.** Human trials must generally be registered before they begin, so a disappointing result leaves a public trace whether or not it is published. Animal research carries no equivalent requirement, so the published animal literature is a filtered sample of an *unknown* total. There is no denominator anywhere. **9. Model answer.** Any number would imply a completeness nobody can verify. Because animal research is largely unregistered, the published literature is a filtered sample of an unknown total, so a count of published studies describes what was published rather than what was done — and stating it as a figure would lend false precision to an unknowable quantity. **10. B.** Approved in a number of countries — notably for hepatitis B and as an immune adjuvant in some jurisdictions — and not FDA-approved in the United States. Both halves belong in the sentence. **11. C.** A split decision is the characteristic external signature of evidence in the genuinely contestable middle: strong enough that some reasonable decision rules clear it, weak enough that others do not. Options A, B, and D all smuggle in the premise that one regulator must be wrong. **12. False.** The indication is part of the approval, not a detail attached to it. An approval for chronic hepatitis B is an approval for chronic hepatitis B — a defined disease in a defined population. It says nothing about general immune support in a healthy person, which is a different claim with a different population and a different endpoint. **13. B.** LL-37 is the principal human cathelicidin: a host-defense antimicrobial peptide with separate immunomodulatory properties. Chapter 25 covers antimicrobial peptides in full. **14. C.** Rule 5 requires that a rating be falsifiable and checkable. A rating issued in a section that explicitly does not present the evidence gives the reader nothing to check, so §18.4 defers. **15. B.** Larazotide is taken orally and designed not to be absorbed, because its proposed target — intestinal tight junctions — is at the apical surface facing the gut lumen. Systemic exposure would add risk with no therapeutic purpose. Poor absorption is a criticism only when absorption was required. **16. B.** KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of α-MSH, with reported anti-inflammatory activity in preclinical models. **17. Model answer.** (i) Direction — "modulate" and "balance" are directionless, compatible with an increase, a decrease, or both. (ii) Immune arm or cell population — "the immune system" comprises many components that move independently and sometimes oppositely. (iii) Measurable endpoint — no assay returns a result on "optimized immune function." (iv) Population — healthy adults, chronic viral infection, post-transplant, and autoimmune are four situations with different and sometimes opposite therapeutic goals. **18. B.** Connection to a clinical outcome. A claim can satisfy the first four specifications, be rigorously tested, and still measure something that does not matter to a patient — because a shifted laboratory value is a surrogate endpoint, and Chapter 6 catalogs how often surrogates have misled. **19. False.** They are different failures with different remedies. TB-500's ❌ means the claim *has not been tested* — a completed trial would resolve it. The "immune modulation" ❌ means the claim *cannot be tested* as stated, because it is compatible with every result. No trial fixes the second; only rewriting the claim does. **20. B.** The same processes a tumor requires. A tumor beyond a minimal size must recruit a blood supply, proliferate, and evade programmed cell death. Note that A overstates and is not supported. **21. C.** No causal link to human cancer is established for any compound in the chapter, *and* the question is unstudied. Both halves are required: A asserts what has not been shown, B asserts safety that has not been demonstrated, and D claims a resolution that does not exist. The absence of evidence of harm from a literature that has not looked for harm is silence, not reassurance. **22. Model answer.** The three states are: (A) studied and disappointing — trials were run and the results were negative or null; (B) not studied — no trials exist, which tells you about funding and incentives rather than about efficacy; and (C) studied in a different molecule — evidence exists but concerns a parent molecule, a different route, or a different species. TB-500 primarily occupies (C), with (B) underneath. (C) is the most misleading because it does not feel like an absence: a search returns real, peer-reviewed papers, and every instinct says the box is filled. The discipline is checking, paper by paper, which molecule was actually studied.